CL2015000717A1 - Compuestos derivados de piridinonas biciclicas y sus sales; composicion farmaceutica que los comprende; y su uso para el tratamiento de la neurodegeneracion y trastornos psiquiatricos, que incluyen enfermedad de alzheimer o enfermedad de niemann-pick tipo c. - Google Patents

Compuestos derivados de piridinonas biciclicas y sus sales; composicion farmaceutica que los comprende; y su uso para el tratamiento de la neurodegeneracion y trastornos psiquiatricos, que incluyen enfermedad de alzheimer o enfermedad de niemann-pick tipo c.

Info

Publication number
CL2015000717A1
CL2015000717A1 CL2015000717A CL2015000717A CL2015000717A1 CL 2015000717 A1 CL2015000717 A1 CL 2015000717A1 CL 2015000717 A CL2015000717 A CL 2015000717A CL 2015000717 A CL2015000717 A CL 2015000717A CL 2015000717 A1 CL2015000717 A1 CL 2015000717A1
Authority
CL
Chile
Prior art keywords
disease
niemann
neurodegeneration
salts
treatment
Prior art date
Application number
CL2015000717A
Other languages
English (en)
Spanish (es)
Inventor
Patrick Robert Verhoest
Antonia Friederike Stepan
Ende Christopher William Am
Michael Eric Green
Douglas Scott Johnson
Gregory Wayne Kauffman
Christopher John O'donnell
Nandini Chaturbhai Patel
Martin Youngjin Petterson
Cory Michael Stiff
Chakrapani Subramanyam
Tuan Phong Tran
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CL2015000717A1 publication Critical patent/CL2015000717A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
CL2015000717A 2012-09-21 2015-03-20 Compuestos derivados de piridinonas biciclicas y sus sales; composicion farmaceutica que los comprende; y su uso para el tratamiento de la neurodegeneracion y trastornos psiquiatricos, que incluyen enfermedad de alzheimer o enfermedad de niemann-pick tipo c. CL2015000717A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261703969P 2012-09-21 2012-09-21

Publications (1)

Publication Number Publication Date
CL2015000717A1 true CL2015000717A1 (es) 2015-06-19

Family

ID=49585452

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015000717A CL2015000717A1 (es) 2012-09-21 2015-03-20 Compuestos derivados de piridinonas biciclicas y sus sales; composicion farmaceutica que los comprende; y su uso para el tratamiento de la neurodegeneracion y trastornos psiquiatricos, que incluyen enfermedad de alzheimer o enfermedad de niemann-pick tipo c.

Country Status (46)

Country Link
US (3) US8916564B2 (enEXAMPLES)
EP (1) EP2897956B1 (enEXAMPLES)
JP (1) JP5844018B2 (enEXAMPLES)
KR (1) KR101725696B1 (enEXAMPLES)
CN (1) CN104662021B (enEXAMPLES)
AP (1) AP2015008277A0 (enEXAMPLES)
AR (1) AR092628A1 (enEXAMPLES)
AU (1) AU2013319845B2 (enEXAMPLES)
BR (1) BR112015006436A2 (enEXAMPLES)
CA (1) CA2882386C (enEXAMPLES)
CL (1) CL2015000717A1 (enEXAMPLES)
CR (1) CR20150053A (enEXAMPLES)
CU (1) CU20150021A7 (enEXAMPLES)
CY (1) CY1118662T1 (enEXAMPLES)
DK (1) DK2897956T3 (enEXAMPLES)
DO (1) DOP2015000069A (enEXAMPLES)
EA (1) EA026668B1 (enEXAMPLES)
EC (1) ECSP15015594A (enEXAMPLES)
ES (1) ES2609987T3 (enEXAMPLES)
GE (1) GEP201706659B (enEXAMPLES)
GT (1) GT201500069A (enEXAMPLES)
HR (1) HRP20161558T1 (enEXAMPLES)
HU (1) HUE031248T2 (enEXAMPLES)
IL (1) IL237163A (enEXAMPLES)
IN (1) IN2015DN01119A (enEXAMPLES)
LT (1) LT2897956T (enEXAMPLES)
MA (1) MA37886B1 (enEXAMPLES)
MD (1) MD4583B1 (enEXAMPLES)
ME (1) ME02571B (enEXAMPLES)
MX (1) MX360599B (enEXAMPLES)
MY (1) MY181891A (enEXAMPLES)
NI (1) NI201500038A (enEXAMPLES)
NZ (1) NZ704863A (enEXAMPLES)
PE (1) PE20150686A1 (enEXAMPLES)
PH (1) PH12015500376A1 (enEXAMPLES)
PL (1) PL2897956T3 (enEXAMPLES)
PT (1) PT2897956T (enEXAMPLES)
RS (1) RS55426B1 (enEXAMPLES)
SG (1) SG11201501074WA (enEXAMPLES)
SI (1) SI2897956T1 (enEXAMPLES)
TN (1) TN2015000084A1 (enEXAMPLES)
TW (1) TWI500616B (enEXAMPLES)
UA (1) UA110688C2 (enEXAMPLES)
UY (1) UY35039A (enEXAMPLES)
WO (1) WO2014045156A1 (enEXAMPLES)
ZA (1) ZA201501195B (enEXAMPLES)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
AU2013366668B2 (en) 2012-12-20 2017-07-20 Janssen Pharmaceutica Nv Novel tricyclic 3,4-dihydro-2H-pyrido[1,2-alpha]pyrazine -1,6-dione derivatives as gamma secretase modulators
US10246454B2 (en) 2013-01-17 2019-04-02 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
EP3052495B1 (en) * 2013-10-04 2019-06-26 Pfizer Inc Novel bicyclic pyridinones as gamma-secretase modulators
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
PE20161364A1 (es) * 2014-04-01 2016-12-25 Pfizer CROMENO Y 1,1a,2,7b-TETRAHIDROCICLOPROPA [C] CROMENO PIRIDOPIRAZINADIONAS NOVEDOSAS
MX368391B (es) * 2015-02-03 2019-09-30 Pfizer Ciclopropabenzofuranil-piridopirazindionas novedosas.
WO2016201168A1 (en) 2015-06-10 2016-12-15 Forum Pharmceuticals Inc. Oxadiazine compounds and methods of use thereof
WO2017216279A1 (en) 2016-06-16 2017-12-21 F. Hoffmann-La Roche Ag Heteroaryl estrogen receptor modulators and uses thereof
WO2018111926A2 (en) 2016-12-16 2018-06-21 Inception 3, Inc. Methods of treating cochlear synaptopathy
WO2020072601A1 (en) 2018-10-02 2020-04-09 Frequency Therapeutics, Inc. Pharmaceutical compositions comprising otic therapeutic agents and related methods
MX2021012258A (es) 2019-04-08 2022-01-04 Frequency Therapeutics Inc Combinacion de chir99021 y acido valproico para tratar la perdida auditiva.
WO2021113627A1 (en) 2019-12-06 2021-06-10 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
CN113402490B (zh) * 2021-03-29 2023-01-03 白银京宇新药业有限公司 一种1，2，6，7-四氢-8H-茚并[5，4-b]呋喃-8-酮的制备方法
WO2022256622A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
CN114034792B (zh) * 2021-11-09 2024-06-25 山东新华制药股份有限公司 检测氯酮含量的液相色谱分析方法

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1419788A (en) 1972-08-02 1975-12-31 Pfizer Herbicidal method using 2-trifuluromethyl-4-quinolinols
WO1992000075A1 (en) 1990-06-29 1992-01-09 Pfizer Inc. Pyridopyrazine derivatives for treating substance abuse and addiction
ATE161530T1 (de) 1992-09-04 1998-01-15 Takeda Chemical Industries Ltd Kondensierte heterozyklische verbindungen, deren herstellung und verwendung
ATE239797T1 (de) 1993-01-25 2003-05-15 Takeda Chemical Industries Ltd Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
ES2194937T3 (es) 1995-03-24 2003-12-01 Takeda Chemical Industries Ltd Compuestos ciclicos, su produccion y uso como antagonistas de los receptores de taquiquinina.
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
DK0994728T3 (da) 1997-04-09 2008-12-01 Intellect Neurosciences Inc Rekombinante antistoffer, som er specifikke for beta-amyloide ender, DNA, der koder derfor, samt fremgangsmåder til anvendelse heraf
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
AU2787299A (en) 1998-03-03 1999-09-20 Ppg Industries Ohio, Inc. Impregnated glass fiber strands and products including the same
US20020132817A1 (en) 1998-03-19 2002-09-19 Hideaki Natsugari Heterocyclic compounds, their production and use
CA2352612A1 (en) 1998-11-27 2000-06-08 Hideo Fukui Pharmaceuticals
CZ304211B6 (cs) 2000-02-24 2014-01-08 Washington University Humanizovaná protilátka, její fragment a jejich použití, polynukleová kyselina, expresní vektor, buňka a farmaceutický prostředek
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
JP4708675B2 (ja) 2000-11-03 2011-06-22 プロテオテック・インコーポレーテッド ウンカリア・トメントーサおよび関連植物からアミロイド阻害化合物を単離する方法ならびに単離した化合物の使用
EP1432444A4 (en) 2001-08-17 2005-11-02 Lilly Co Eli ANTI-BETA ANTIBODIES
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
CA2498111A1 (en) 2002-09-11 2004-03-25 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors
BR0315157A (pt) 2002-10-09 2005-08-09 Rinat Neuroscience Corp Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
CA2501799C (en) 2002-10-09 2008-06-17 Pfizer Products Inc. Pyrazole compounds for treatment of neurodegenerative disorders
US20040157804A1 (en) 2002-10-16 2004-08-12 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
BRPI0410630A (pt) 2003-06-19 2006-06-13 Pfizer Prod Inc antagonista de nk1
BRPI0413709A (pt) 2003-08-21 2006-10-17 Pfizer Prod Inc compostos para o tratamento de distúrbios neurodegenerativos
CA2538220A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
WO2005072361A2 (en) 2004-01-28 2005-08-11 Merck & Co., Inc. Aminocyclopentyl pyridopyrazinone modulators of chemokine receptor activity
JP2007519707A (ja) 2004-02-02 2007-07-19 ファイザー・プロダクツ・インク ヒスタミン−３受容体モジュレーター
CA2557785A1 (en) 2004-03-09 2005-10-06 Merck & Co. Inc. Hiv integrase inhibitors
ATE399155T1 (de) 2004-03-23 2008-07-15 Pfizer Prod Inc Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
CA2562713A1 (en) 2004-04-14 2005-12-15 Gilead Sciences, Inc. Phosphonate analogs of hiv integrase inhibitor compounds
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
EP2298807A3 (en) 2004-07-30 2011-05-18 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
FR2877015B1 (fr) 2004-10-21 2007-10-26 Commissariat Energie Atomique Revetement nanostructure et procede de revetement.
GB0423356D0 (en) 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
US20090074775A1 (en) 2004-12-22 2009-03-19 David Michael Holtzman Use Of Anti-AB Antibody To Treat Traumatic Brain Injury
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
AU2006244424B2 (en) 2005-05-10 2011-09-22 Merck Sharp & Dohme Corp. HIV integrase inhibitors
US8227475B2 (en) 2005-05-12 2012-07-24 Pfizer Inc. Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
WO2006126083A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
CA2603830A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Co Llc PYRIDINE [2,3-B] PYRAZINONES
WO2006126082A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
ATE488496T1 (de) 2005-06-22 2010-12-15 Pfizer Prod Inc Histamin-3-rezeptorantagonisten
US20070060534A1 (en) 2005-06-30 2007-03-15 Threshold Pharmaceuticals, Inc. Anthracycline analogs
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
JP2009514846A (ja) 2005-11-04 2009-04-09 ファイザー・リミテッド テトラヒドロナフチリジン誘導体
US20080275251A1 (en) 2005-11-18 2008-11-06 Glaxo Group Limited Novel Intermediates and Their Use
EP1948614A2 (en) 2005-11-18 2008-07-30 Takeda San Diego, Inc. Glucokinase activators
MY144960A (en) 2005-11-24 2011-11-30 Eisai R&D Man Co Ltd Morpholine type cinnamide compound
US20070117839A1 (en) 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
WO2007084595A2 (en) 2006-01-20 2007-07-26 Schering Corporation Carbocyclic and heterocyclic arylsulfones as gamma secretase inhibitors
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
EP2007749A2 (en) 2006-03-13 2008-12-31 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
PL2013208T3 (pl) 2006-04-21 2011-10-31 Pfizer Prod Inc Pirydyno[3,4-B]pirazynowy
EP2021327B1 (en) 2006-05-15 2012-04-04 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
NZ572367A (en) 2006-05-16 2011-09-30 Gilead Sciences Inc Fused cyclic compounds as integrase inhibitors
JPWO2007135969A1 (ja) 2006-05-19 2009-10-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア系−シンナミド誘導体
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
SI2124933T1 (sl) 2007-01-22 2012-12-31 Pfizer Products Inc. Tosilatna sol terapevtske spojine in farmacevtski sestavi tega
US8252803B2 (en) 2007-02-12 2012-08-28 Merck Sharp & Dohme Corp. Piperidine derivatives
EP2121633A2 (en) 2007-02-12 2009-11-25 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
PE20081791A1 (es) 2007-02-28 2009-02-07 Eisai Randd Man Co Ltd Dos derivados ciclicos de oxomorfolina
WO2008137102A2 (en) 2007-05-04 2008-11-13 Torreypines Therapeutics, Inc. Methods of modulating amyloid beta and compounds useful therefor
EP2155737A1 (en) 2007-05-07 2010-02-24 Schering Corporation Gamma secretase modulators
MX2009012163A (es) 2007-05-11 2009-12-01 Hoffmann La Roche Hetarilanilinas como moduladores para beta-amiloide.
TW200908968A (en) 2007-05-29 2009-03-01 Sgx Pharmaceuticals Inc Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators
AU2008263207B2 (en) 2007-06-01 2013-10-03 Merck Sharp & Dohme Corp. Gamma secretase modulators
EP2164852A2 (en) 2007-06-01 2010-03-24 Schering Corporation Gamma secretase modulators
EP2166854A4 (en) 2007-06-13 2012-05-16 Merck Sharp & Dohme TRIAZONE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED SUFFERINGS
CL2008001914A1 (es) 2007-06-29 2009-07-17 Schering Corp Compuestos heterociclicos de nitrogeno y oxigeno,moduladores de gama secretasa, composicion farmaceutica de dichos compuestos; kit farmaceutico y su uso para prevenir o tratar enfermedades asociadas al sistema nervioso central como alzheimer, sindrome de down, enfermedades neurodegenerativas, inhibir el deposito de proteina amiloide.
MX2010001506A (es) 2007-08-06 2010-03-10 Schering Corp Moduladores de gamma secretasa.
MX2010002098A (es) 2007-08-31 2010-03-30 Eisai R&D Man Co Ltd Compuesto policiclico.
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
CN101848897A (zh) 2007-09-06 2010-09-29 先灵公司 γ分泌酶调节剂
MX2010003397A (es) 2007-09-28 2010-04-09 Schering Corp Moduladores de la gamma secretasa.
GB0720444D0 (en) 2007-10-18 2007-11-28 Glaxo Group Ltd Novel compounds
WO2009061699A1 (en) 2007-11-05 2009-05-14 Schering Corporation Gamma secretase modulators
CN101939312A (zh) * 2007-12-06 2011-01-05 先灵公司 γ分泌酶调节剂
CA2708151A1 (en) 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
JP2011506461A (ja) 2007-12-11 2011-03-03 シェーリング コーポレイション γ−セクレターゼモジュレーター
EP2231602A1 (en) 2007-12-13 2010-09-29 Amgen, Inc Gamma secretase modulators
EP2231629B1 (en) 2008-01-11 2011-11-30 F. Hoffmann-La Roche AG Modulators for amyloid beta
EP2257541B1 (en) 2008-02-22 2013-08-14 F. Hoffmann-La Roche AG Modulators for amyloid beta
US20100137320A1 (en) 2008-02-29 2010-06-03 Schering Corporation Gamma secretase modulators
EP2257542A1 (en) 2008-02-29 2010-12-08 Schering Corporation Gamma secretase modulators for the treatment of alzheimer ' s disease
CA2722606A1 (en) 2008-05-05 2009-11-12 Amgen Inc. Urea compounds as gamma secretase modulators
FR2933700B1 (fr) * 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
TW201006801A (en) 2008-07-18 2010-02-16 Lilly Co Eli Imidazole carboxamides
WO2010019393A1 (en) 2008-08-13 2010-02-18 Merck Sharp & Dohme Corp. Pyrimidine derivatives for treatment of alzheimer's disease
US20110251172A1 (en) 2008-08-13 2011-10-13 Rivkin Alexey A Purine derivatives for treatment of alzheimer's disease
JP2012501336A (ja) 2008-08-27 2012-01-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 シンナミド化合物の製造法
WO2010040661A1 (en) 2008-10-09 2010-04-15 F. Hoffmann-La Roche Ag Modulators for amyloid beta
WO2010054064A1 (en) 2008-11-06 2010-05-14 Schering Corporation Gamma secretase modulators
MX2011004680A (es) 2008-11-06 2011-05-25 Astrazeneca Ab Moduladores de beta amiloide.
AU2009313527A1 (en) 2008-11-06 2010-05-14 Merck Sharp & Dohme Corp. Gamma secretase modulators
JP5378532B2 (ja) 2008-11-10 2013-12-25 エフ．ホフマン−ラ ロシュ アーゲー 複素環γ−セクレターゼモジュレーター
EP2379075A4 (en) 2008-12-16 2012-05-30 Merck Sharp & Dohme TRIAZOL DERIVATIVES FOR THE TREATMENT OF ALZHEIMER DISEASE
US8575150B2 (en) 2008-12-16 2013-11-05 Merck Sharp & Dohme Corp. Triazole derivatives for treatment of Alzheimer's disease
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
JP2012512834A (ja) 2008-12-19 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症、喘息及びｃｏｐｄの処置のためのｃｃｒ２受容体アンタゴニストとしての環状ピリミジン−４−カルボキサミド
US20120135980A1 (en) 2008-12-22 2012-05-31 Theodros Asberom Gamma secretase modulators
EP2379563B1 (en) 2008-12-22 2014-07-16 Merck Sharp & Dohme Corp. Gamma secretase modulators
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
NZ593951A (en) 2009-02-06 2013-01-25 Ortho Mcneil Janssen Pharm Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
JP2012051807A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
JP2012051805A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd テトラヒドロトリアゾロピリジン誘導体の製造方法
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
BRPI1007883A2 (pt) 2009-02-26 2016-02-23 Eisai R&D Man Co Ltd sal, e, cristal.
JP2012121809A (ja) 2009-02-26 2012-06-28 Eisai R & D Management Co Ltd 多環式化合物の製造法およびその中間体
EP2403835A1 (en) 2009-03-03 2012-01-11 Pfizer Inc. Novel phenyl imidazoles and phenyl triazoles as gamma-secretase modulators
JP5771207B2 (ja) 2009-08-07 2015-08-26 ダウ アグロサイエンシィズ エルエルシー 有害生物防除組成物
JP2013508350A (ja) * 2009-10-20 2013-03-07 ファイザー・インク ガンマ−セクレターゼモジュレーターとしての新規なヘテロアリールイミダゾールおよびヘテロアリールトリアゾール
CN102762548B (zh) * 2009-12-22 2014-11-26 沃泰克斯药物股份有限公司 磷脂酰肌醇3-激酶的异吲哚啉酮抑制剂
ES2602794T3 (es) * 2011-03-31 2017-02-22 Pfizer Inc Piridinonas bicíclicas novedosas
NZ702611A (en) * 2012-05-16 2016-10-28 Cellzome Ltd Substituted 3, 4 - dihydro - 2h - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) alzheimer’s disease
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
TWI614238B (zh) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
AU2013366668B2 (en) 2012-12-20 2017-07-20 Janssen Pharmaceutica Nv Novel tricyclic 3,4-dihydro-2H-pyrido[1,2-alpha]pyrazine -1,6-dione derivatives as gamma secretase modulators
US10246454B2 (en) 2013-01-17 2019-04-02 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
EP3052495B1 (en) 2013-10-04 2019-06-26 Pfizer Inc Novel bicyclic pyridinones as gamma-secretase modulators
CN106413623B (zh) 2014-03-21 2020-07-03 阿莱恩技术有限公司 具有弹性体的分段的正畸矫正器
PE20161364A1 (es) 2014-04-01 2016-12-25 Pfizer CROMENO Y 1,1a,2,7b-TETRAHIDROCICLOPROPA [C] CROMENO PIRIDOPIRAZINADIONAS NOVEDOSAS

Also Published As

Publication number Publication date
CY1118662T1 (el) 2017-07-12
US20140088111A1 (en) 2014-03-27
RS55426B1 (sr) 2017-04-28
US20160024088A1 (en) 2016-01-28
GT201500069A (es) 2016-03-01
HUE031248T2 (en) 2017-06-28
EA026668B1 (ru) 2017-05-31
US20150072990A1 (en) 2015-03-12
KR20150044948A (ko) 2015-04-27
PH12015500376B1 (en) 2015-04-20
PL2897956T3 (pl) 2017-05-31
EP2897956A1 (en) 2015-07-29
MD20150023A2 (ro) 2015-07-31
MX360599B (es) 2018-11-08
LT2897956T (lt) 2017-01-10
UY35039A (es) 2014-04-30
KR101725696B1 (ko) 2017-04-10
ES2609987T3 (es) 2017-04-25
CR20150053A (es) 2015-03-25
PT2897956T (pt) 2017-01-13
DOP2015000069A (es) 2015-05-15
SG11201501074WA (en) 2015-05-28
US9751877B2 (en) 2017-09-05
PE20150686A1 (es) 2015-05-23
EP2897956B1 (en) 2016-11-09
TW201425311A (zh) 2014-07-01
HK1206013A1 (zh) 2015-12-31
ZA201501195B (en) 2016-01-27
NZ704863A (en) 2017-03-31
CU20150021A7 (es) 2015-08-27
AR092628A1 (es) 2015-04-29
CN104662021A (zh) 2015-05-27
ME02571B (me) 2017-06-20
GEP201706659B (en) 2017-04-25
DK2897956T3 (en) 2017-01-16
SI2897956T1 (sl) 2017-02-28
AU2013319845B2 (en) 2017-09-14
AU2013319845A1 (en) 2015-02-26
US9193726B2 (en) 2015-11-24
AP2015008277A0 (en) 2015-02-28
MX2015003637A (es) 2015-06-05
CA2882386C (en) 2017-11-28
EA201590319A1 (ru) 2015-09-30
MA37886A1 (fr) 2016-02-29
ECSP15015594A (es) 2017-08-31
IL237163A (en) 2016-12-29
CN104662021B (zh) 2016-08-24
TN2015000084A1 (fr) 2016-06-29
TWI500616B (zh) 2015-09-21
JP5844018B2 (ja) 2016-01-13
WO2014045156A1 (en) 2014-03-27
JP2015529238A (ja) 2015-10-05
IL237163A0 (en) 2015-04-30
HRP20161558T1 (hr) 2016-12-30
MD4583B1 (ro) 2018-07-31
IN2015DN01119A (enEXAMPLES) 2015-06-26
CA2882386A1 (en) 2014-03-27
NI201500038A (es) 2015-06-05
PH12015500376A1 (en) 2015-04-20
UA110688C2 (uk) 2016-01-25
BR112015006436A2 (pt) 2017-07-04
MY181891A (en) 2021-01-12
MA37886B1 (fr) 2016-09-30
US8916564B2 (en) 2014-12-23

Similar Documents

Publication Publication Date Title
CL2015000717A1 (es) Compuestos derivados de piridinonas biciclicas y sus sales; composicion farmaceutica que los comprende; y su uso para el tratamiento de la neurodegeneracion y trastornos psiquiatricos, que incluyen enfermedad de alzheimer o enfermedad de niemann-pick tipo c.
CL2014000806A1 (es) Compuestos derivados de 1-arilcarbonil-4-oxi-piperidino; composicion farmaceutica que los comprende; uso para la prevencion o el tratamiento de enfermedades neurodegenerativas tales como enfermedad de alzheimer, enfermedad de parkinson, enfermedad de huntington o esclerosis multiple.
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2015000408A1 (es) Compuestos derivados de pirazolo[4,3-d]pirimidina y sus sales; composicion farmaceutica que los comprende, util para el tratamiento de enfermedades alergicas, inflamatorias, infecciosas o cancer.
EP3305103A4 (en) atomizing
SV2017005426A (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
EP3315035A4 (en) atomizing
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2014001855A1 (es) Compuestos derivados de imidazopirrolidinona o sus sales, formas cristalinas; composicion farmaceutica que los comprende; y su uso para el tratamiento de un trastorno o enfermedad mediada por la actividad de mdm2 y/o mdm4 tales como enfermedades proliferativas, especialmente cancer.
CL2016001595A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6.
ITUA20161510A1 (it) Composizione per colorare la fibra cheratinica
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
CL2015001733A1 (es) Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer.
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
CL2014001060A1 (es) Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades.
CL2015001279A1 (es) Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras.
CL2015000615A1 (es) Compuestos derivados de 4-amino-quinolinas, inhibidores de rip2 cinasa; composicion farmaceutica que los comprende; uso para el tratamiento de enfermedades tales como enfermedad de crohn, colitis ulcerativa o sindrome de blau.
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
CL2013001604A1 (es) Compuestos derivados de pirimidinona sustituida; composicion farmaceutica que los comprende; su uso para tratar la enfermedad de alzheimer y la aterosclerosis.
CL2014000246A1 (es) Compuestos derivados fenil-3-aza-biciclo[3.1.0]hex-3-il-metanonas, inhibidores del transportador de glicina (glyt1); composicion farmaceutica que los contiene; combinacion farmaceutica; y su uso en el tratamiento de alzheimer, alteraciones cognitivas en esquizofrenia, psicosis, trastornos psiquiatricos, entre otros
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
CL2016000884A1 (es) Derivados de piperazina y su uso como medicamento.
MA45451A (fr) Formulations tensioactives destinées à l'inhalation
EP3459369A4 (en) PHARMACEUTICAL COMPOSITION WITH LACTOBACILLUS SP. KCCM 11826P STRAIN FOR PREVENTING HYPERPHOSPHATMA AND TREATING CHRONIC KIDNEY DISEASE AND HEALTH FUNCTIONAL FOOD
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.